CEL-SCI Cancer Treatment Shows 73% Survival Rate, FDA Clears Path to Market

CEL-SCI Cancer Treatment Shows 73% Survival Rate, FDA Clears Path to Market

CEL-SCI advances Multikine for head and neck cancer with FDA protocol clearance. Manufacturing facility ready as company seeks partners for final study with strong Phase 3 data.

The Future of Cancer Treatment: A Breakthrough Molecule Offers Hope for Head and Neck Cancers

Dr. Judy Sebolt-Leopold leads a revolution in targeted cancer therapies with MTX-531 at the University of Michigan. MTX-531 targets and inhibits EGFR and PI3K protein kinases, offering a more precise cancer treatment. The molecule’s “flipped binding mode” effectively tackles adaptive resistance and minimizes severe side effects. In preclinical trials, MTX-531 has shown significant success, particularly in head and neck cancers, by promoting dura…